Kornimate/medical-research-clean huggingface dataset:
qigong therapy for individuals with knee osteoarthritis

Conditions: Osteoarthritis

Summary: the purpose of this study is to evaluate the effectiveness of qigong therapy, an ancient chinese practice, for pain relief and symptom improvement in people with knee osteoarthritis (oa). study hypotheses: 1) qigong therapy will result in greater reduction of pain and greater symptom improvement than sham treatment. 2) individuals with a history of complementary and alternative medicine (cam) use will be more likely to experience benefits of qigong therapy than those without such experience.

oa is the leading cause of disability in the united states. standard treatment for oa is drug therapy; however, cost, side effects, and varying levels of effectiveness warrant the need for development of new treatments. qigong therapy, which involves deep meditation, breathing exercises, and the harnessing of energy, may be an effective treatment for oa. according to traditional chinese medicine, qi (chi) is the "life force" that flows through the body and keeps people healthy and vital. in the practice of traditional chinese medicine, arthritis is thought to be due to a blockage of the flow of qi or a buildup of abnormal or damaging qi. it is believed that releasing this buildup or breaking the blockage of qi through qigong therapy may relieve oa symptoms. participants will be randomly assigned to receive five sessions of either qigong therapy or sham treatment over a period of 2 weeks. during qigong therapy, a therapist will send his or her qi to the arthritic knees through touch and meditation. similar body work will be performed during the sham treatment, but no qi will be harnessed. self-report scales that measure pain, stiffness, anxiety, daily drug use, cam use, and overall functioning will be used to assess participants. the assessments will occur at study start and at a 3-month follow-up visit.

Eligibility criteria:
inclusion criteria: * diagnosis of osteoarthritis at least 6 months prior to study entry * able to understand english exclusion criteria: * inflammatory joint disease affecting leg movement * knee replacement surgery on the oa knee * depo-corticosteroid knee injections within 3 months prior to study entry * pain in hips or lower back affecting leg movement * new arthritis drugs or other painkillers within 2 weeks prior to study entry * investigational drugs within 30 days prior to study entry * asthma requiring oral corticosteroids within 4 weeks prior to study entry

Keywords: knee pain arthritis qigong qi meditation breathing exercises
improved estimation of gfr by cystatin c in preventing contrast induced nephropathy by nac or zn

Conditions: Chronic Kidney Failure

Summary: background prevention of contrast media (cm) induced nephropathy (cin) by pharmacological prophylaxis (e.g. n-acetylcysteine; nac) is controversially discussed. so far, in all interventional studies assessment of kidney function was based on measurements of serum creatinine although this surrogate biomarker has several limitations. we investigated the antioxidants nac and zinc (zn) for the prevention of cin by monitoring concomitantly serum levels of creatinine and cystatin c.

in a prospective, placebo-controlled, double blind trial patients with moderate impaired kidney function receiving hypoosmolar, nonionic contrast medium were randomly assigned to an oral treatment for 2 days with 1.2g/day of nac (n=19), for 1 day with 60mg/day of zn (n=18) or placebo (n=17). all patients were periprocedural hydrated with 1ml/kg/h of 0.45% saline for 24h. at baseline (before hydration), prior to exposure of cm as well as 2 and 6 days after cm serum levels of creatinine and cystatin c have been measured.

Eligibility criteria:
inclusion criteria: 1. older than 18 years of age, 2. serum creatinine \> 1.2 mg/dl or a creatinine clearance \< 50 ml/min (measured by a 12 or 24 hour urine collection). exclusion criteria: 1. acute inflammatory disease, 2. medication with nsaid or metformin until 3 days before entering study, 3. abnormal findings in physical examinations, e.g. signs of dehydration or decompensated heart failure.

Keywords: contrast-induced nephropathy acetylcysteine zinc cystatin c creatinine
effectiveness of phototherapy with and without probiotics

Conditions: Hyperbilirubinemia, Neonatal

Summary: raised serum bilirubin levels can cause kernicterus and premature infants are at increased risk due to metabolic immaturity. the standard treatment for neonatal jaundice is phototherapy but probiotics along with it can reduce the duration of phototherapy and hospitalization stay, secondarily can reduce the risk of nosocomial infection.

raised serum bilirubin levels can cause kernicterus and premature infants are at increased risk due to metabolic immaturity. the comparative analytical study was conducted after the ethical approval for one year (jan 2022-jan 2023) in the neonatal unit of the university of lahore teaching hospital, lahore, pakistan. 76 preterm neonates fulfilling the selection criteria were included in the study and divided into two groups. standard phototherapy was applied in both groups and group a probiotic (saccharomyces boulardii) 125mg, twice daily, orally (in 5cc of milk whichever the baby was taking) was given till discharge from the hospital. the primary outcome measurements were the duration of phototherapy and the length of hospitalization.

Eligibility criteria:
inclusion criteria: * all the neonates with indirect hyperbilirubinemia, * born at ;37 weeks of gestation * both male and female neonates were included in the study exclusion criteria: * neonates with sepsis, * bilirubin level in exchange transfusion range * direct hyperbilirubinemia * neonates with respiratory distress syndrome, severe birth asphyxia, intubated and critically sick
feasibility of sentinel lymph node biopsy in rectal cancer

Conditions: Rectal Cancer

Summary: this study will assess whether the sienna+/sentimag system, which involves a magnetic tracer, is effective in identifying the sentinel lymph node in rectal cancer and whether it is then feasible to remove this lymph node during surgery to locally excise early rectal cancer.

one issue in managing rectal cancer is identifying which patients will benefit from less radical surgery, which is much safer and better tolerated. however it does not remove lymph nodes where cancer cells may have spread. if lymph nodes containing cancer are left behind, the cancer may recur. so this surgery is only suitable in early rectal cancers not involving lymph nodes. unfortunately, current investigations do not always accurately identify involved lymph nodes. sentinel lymph node biopsy (slnb) is a technique to surgically remove the first lymph node where cancer cells spread. if this lymph node contains cancer, radical surgery is needed to reduce the risk of recurrence. however if it is clear, less radical surgery should be sufficient. this is standard practice for breast cancer and avoids unnecessary major surgery in many patients. the investigators aim to assess whether slnb is useful in rectal cancer. the investigators will determine whether the sienna+/sentimag system effectively identifies the sentinel lymph node, and whether the node can then be removed surgically. the investigators will recruit patients in oxford hospitals about to undergo surgery for rectal cancer. patients will receive an injection of magnetic tracer during endoscopy prior to surgery. some patients will have an extra mri scan. during or after surgery, depending on the type of operation planned, a magnetic probe will be used to locate the sentinel lymph node in the tissue around the rectum. the removed specimen will be examined by a pathologist. funding to undertake this study has been granted by the national institute for health research (nihr). endomagnetics, the manufacturer, will supply the magnetic tracer and probe for use in this study. if successful, the investigators will plan a larger clinical trial. this could have a major impact on improving outcomes for patients by allowing less radical surgery to be used where it is most appropriate.

Eligibility criteria:
inclusion criteria: * diagnosed with operable rectal cancer * case discussed at oxford colorectal cancer multi-disciplinary team (mdt) meeting * willing and able to give informed consent * willing and able to comply with all trial requirements, in the investigator's opinion exclusion criteria: * females who are pregnant or lactating * known intolerance or hypersensitivity to iron, dextran compounds, magnetic tracers or superparamagnetic iron oxide particles (spio) * cancer involvement of anal sphincter complex * adults who are not able to give consent or are deemed vulnerable

Keywords: rectal cancer sentinel lymph node biopsy
efficacy/ safety of dnn.22.17.036 in male patients with pattern hair loss

Conditions: Alopecia

Summary: evaluation of the efficacy and safety of dnn.22.17.036 versus 10573048700 in the treatment of male pattern hair loss.


Eligibility criteria:
inclusion criteria: * ability to understand and consent to participate in this clinical research, expressed by signing the informed consent form (icf) * male participants age 25 or older and 60 age or younger * participants who have an intact scalp in the area of product analysis * participants with androgenetic alopecia (aga) with aga norwood-hamilton scale \> ii * participants with at least 20% telogen effluvium of evaluated by tricholab exclusion criteria: * participants who have used immunosuppressants in the 3 months prior to signing the icf * participants with other causes of hair loss or scalp dermatoses * participants who have received hair loss treatment in the last 6 months * participants with uncontrolled medical conditions, kidney and liver disease * participants with a history of hair transplantation, malignancy, hematologic disorders, thyroid dysfunction, malnutrition, and other dermatologic disorders that contribute to hair loss
radiation therapy to the abdomen plus docetaxel in treating patients with recurrent or persistent advanced ovarian, peritoneal, or fallopian tube cancer

Conditions: Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma; Recurrent Ovarian Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer

Summary: phase i trial to study the effectiveness of low-dose radiation therapy to the abdomen combined with docetaxel in treating patients who have recurrent or persistent advanced ovarian, peritoneal, or fallopian tube cancer. radiation therapy uses high-energy x-rays to damage tumor cells. drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. combining chemotherapy with radiation therapy may kill more tumor cells.

objectives: i. determine the maximum tolerated dose of docetaxel in combination with low-dose abdominal radiotherapy in patients with recurrent or persistent advanced ovarian, peritoneal, or fallopian tube cancer. ii. determine the safety and toxicity of this regimen in these patients. outline: this is a multicenter, dose-escalation study of docetaxel. patients receive docetaxel iv over 30 minutes once daily on days 1, 8, 15, 22, 29, and 35. within 3 hours after beginning docetaxel, patients also receive low-dose abdominal radiotherapy twice daily (at least 4 hours apart) on days 1, 2, 8, 9, 15, 16, 22, 24, 29, 30, 35, and 36. treatment continues in the absence of unacceptable toxicity. cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Eligibility criteria:
inclusion criteria: * diagnosis of ovarian, peritoneal, or fallopian tube carcinoma * radiographic, clinical, or pathologic evidence of relapse * recurrent or persistent disease after chemotherapy (may be enrolled at first or subsequent relapse) * received prior taxane or platinum agent * performance status - gog 0-1 * wbc at least 3,000/mm\^3 * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 * bilirubin no greater than 1.5 times upper limit of normal (uln) * sgot/sgpt no greater than 2.5 times uln * alkaline phosphatase no greater than 2.5 times uln * creatinine no greater than 1.5 times uln * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception * no grade 2 or greater neuropathy (sensory or motor) * no septicemia * no severe infection * no circumstance that would preclude study completion * no prior radiotherapy to the abdomen or pelvis * patients with ureteral obstruction must undergo stent or nephrostomy tube replacement prior to study entry
single dose study to determine the safety, tolerability, and pharmacokinetic properties of lorcaserin hydrochloride (belviq) in obese adolescents from 12 to 17 years of age

Conditions: Pharmacokinetics in Obese Adolescents

Summary: the purpose of this study is to evaluate the pk properties, tolerability, and safety of lorcaserin hcl (belviq) in obese adolescent subjects between the ages of 12 to 17 years old

the purpose is to: 1. assess the single-dose pharmacokinetic (pk) parameters of lorcaserin and a primary metabolites (m1 and m5) in obese adolescent subjects ages 12-17 (inclusive) 2. assess the safety and tolerability of a single oral dose of lorcaserin in obese adolescent subjects ages 12-17 (inclusive)

Eligibility criteria:
inclusion criteria: 1. adolescent subjects aged 12 to 17 years, inclusive at screening 2. a. eligible female subjects who are sexually active will be: * non-pregnant * non-lactating * agree to continue to use an accepted method of birth control for at least 1 month after study medication administration 3. bmi ≥ 95th percentile for age and gender, but ≤ 44 kg/m21 4. considered to be in stable health in the opinion of the investigator. 5. parent or guardian who can sign written informed consent and subject willing to sign assent exclusion criteria: 1. clinically significant new illness in the 1 month before screening and any time prior to randomization 2. significant renal or hepatic disease 3. secondary (chromosomal, endocrine, or metabolic) causes of obesity 4. use of medications other than hormonal contraceptives and acetaminophen 5. use of drugs with serotonergic activity within 1 month before screening 6. recent treatment with over-the-counter weight loss products or appetite suppressants, or within 3 months of screening and any time prior to randomization with a prescription weight loss drug or lipid dissolving injections or ongoing psychotherapy for weight loss outside of this trial 7. recent history of alcohol, tobacco, or recreational drug/solvent use 8. any history of major depression, anxiety, bipolar disorder, schizophrenia, or axis ii psychiatric disease requiring treatment with prescription medication within six months prior to screening
clinical trial of sipjeondaebo-tang on fatigue of breast cancer patients

Conditions: Breast Carcinoma

Summary: this is a pilot study that investigate efficacy and safety of sipjeondaebo-tang on fatigue of patients with breast carcinoma receiving chemotherapy.


Eligibility criteria:
inclusion criteria: * men and women aged over 18 years * patients who have histologically or cytologically confirmed breast tumor * patients who applicable ac(doxorubicin + cyclophosphamide) * ecog score 0 to 2 exclusion criteria: * patient impossible to orally intake * patient with dementia, delirium and depression * patient suffering from diseases like chronic hepatitis b, c or hepatocirrhosis * severe liver disability (3-fold the normal high range value for alt, ast) * patient who has diabetes not controlled by diet, hypertension, hyperthyroidism, * severe systemic disease * use of other investigational products within the past 30 days * hypersensitivity to investigational product * others who are judged not to be appropriate to study
risk stratification and early prevention strategies for non-compaction of ventricular myocardium (captain)

Conditions: Isolated Noncompaction of the Ventricular Myocardium

Summary: this study intends to retrospectively-prospectively enroll nvm patients from multiple centers to establish a natural population cohort of nvm patients. by collecting clinical data and biological samples from surgical patients, the investigators will construct a prognosis prediction system for nvm, optimize risk stratification, explore new strategies for the early prevention and treatment of nvm, and improve the efficiency of clinical treatment of nvm patients.

this study intends to retrospectively-prospectively enroll nvm patients from multiple centers to establish a natural population cohort of nvm patients. by collecting clinical data and biological samples from surgical patients, the investigators will construct a prognosis prediction system for nvm, optimize risk stratification, explore new strategies for the early prevention and treatment of nvm, and improve the efficiency of clinical treatment of nvm patients.

Eligibility criteria:
inclusion criteria: * the diagnosis of nvm was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing. * patients or their families agreed to participate in the study and authorized informed consent. exclusion criteria: * incomplete clinical data. * do not agree to the inclusion or refuse to authorize the informed consent.

Keywords: isolated noncompaction of the ventricular myocardium prognostic factors
long-term outcomes after laparoscopic subtotal and total hysterectomy

Conditions: Hysterectomy

Summary: hysterectomy is one of the most commonly performed gynecologic surgeries in the usa. it is used for many benign conditions such as leiomyoma and abnormal uterine bleeding. surgery may involve the removal of the cervix (total hysterectomy, th) or its preservation (supracervical or subtotal hysterectomy, sh). whether th or sh is the best procedure for benign conditions is a matter of debate. considering the lack of evidence, this study aims to evaluate long-term sexual dysfunctions, urinary dysfunctions and pelvic organ prolapse in women who underwent laparoscopic subtotal versus total hysterectomy for benign conditions.


Eligibility criteria:
inclusion criteria: * women who underwent subtotal or total hysterectomy by laparoscopy for benign conditions. exclusion criteria: * women with gynecological and non-gynecological cancers.

Keywords: subtotal laparoscopic hysterectomy total laparoscopic hysterectomy hysterectomy
posterior capsule opacification and frequency of nd:yag treatment and of two iols: hoya imics y-60h vs. bausch&lomb mi60 (mimi)

Conditions: Posterior Capsule Opacification; Cataract

Summary: age-related cataract is the main cause of impaired vision in the elderly population worldwide. the only treatment that can restore functional visual ability is cataract surgery where the opacified crystalline lens is removed by phacoemulsification and an artificial intraocular lens is implanted into the remaining capsular bag. cataract operations are generally very successful, with a low risk of serious complications. the most common reason for impaired vision after uneventful cataract surgery in otherwise healthy eyes is the development of posterior capsule opacification (pco). pco is a physiological change (thickening, opacification and clouding) of the capsular bag expected after cataract surgery, because the lens epithelial cells (lecs) undergo hyperplasia and cellular migration. pco is treated with nd:yag capsulotomy, a quick outpatient procedure that uses a laser to open a central hole in the posterior capsular bag. modifications in iol design and material lead to a decrease in the incidence of pco. during the past two decades, refinements in surgical technique were made resulting in today's small incision phacoemulsification surgery. nowadays a multitude of microincision iols are available, many of them similar but of course with some differences in regard to the chemical composition of the acrylic material and the iol design. the purpose of this study is to compare the development of posterior capsule opacification (pco) and the frequency of treatment between two different microincision iols over a period of 4 years.


Eligibility criteria:
inclusion criteria: * bilateral age-related cataract * good overall physical constitution exclusion criteria: * previous intraocular surgery or ocular trauma * intraocular complication like posterior capsular tear * glaucoma * uveitis * corneal diseases, diabetic retinopathy and any other severe retinal pathology that would make a postoperative visual acuity of 20/40 (decimal equivalent = 0.5) or better unlikely

Keywords: posterior capsule opacification pco after cataract intraocular lens
comparison of analgesic efficacy of quadratus lumborum type 3 and suprainguinal fascia iliaca compartment block in total hip arthroplasty surgery

Conditions: Opioid Consumption; Pain Postoperative

Summary: total hip arthroplasty (tha) is a complex surgical procedure frequently performed to treat degenerative conditions in the hip joint. as people's life expectancy increases, the need for hip arthroplasty increases. i̇nvestigetors aimed to compare the analgesic properties of sifi and qlb blocks.


Eligibility criteria:
inclusion criteria: 1. elective patients scheduled for hip arthroplasty surgery 2. patient willingness to participate in the study 3. patients over 18 years age of, asa i-ii-iii, exclusion criteria: 1. patients not wanting to participate in the study 2. patients who do not want regional anesthesia technique 3. allergic or coagulated patients 4. patients with liver, kidney, lung, heart failure and septic patients 5. neurological disorder, history of convulsions 6. asa iv patients
infective endocarditis in the elderly

Conditions: Infective Endocarditis

Summary: elderl-ie is a multicenter national prospective observational study. the main objective is to describe geriatric characteristics (comorbidities, cognitive status, autonomy, nutritional status, balance and walking) in patients aged 75 years or older with infective endocarditis (ie). the secondary objectives are to assess the impact of geriatric features on the medico - surgical care and on morbidity and mortality at 3 months after the end of the hospitalization, and to describe the initial clinical presentation and diagnostic modalities in the ie elderly.

population monitoring: clinical, therapeutic, biological, microbiological, echocardiographic and geriatric data are collected. (m-2/3 before inclusion; d-15 before inclusion; d0; m3; vital status at 1 year)

Eligibility criteria:
inclusion criteria : * all patients older than 75 years are eligible if they are considered and treated as a case of ie by physicians ensuring their medical care. * the patient should be treated in one of the clinical sites participating at the study. * the patient should benefit during initial hospitalization of a geriatric assessment, in addition to the usual clinical and therapeutic management of such patients. exclusion criteria : * patients not fulfilling the criteria of definite or possible endocarditis according to duke modified by li diagnostic classification that will be applied after collection of all the data at the discharge of the patient.